Even if the science is strong, so many flash in the pan cell therapy startups just can't execute on clinical operations. They get through IPO on investor FOMO and promises of exciting times ahead but then the stock tanks tanks when the trials take forever, cost more than anticipated and no other drugs to fall back on.

Rough market for the 127 people laid off.